Blog

On June 5th, 2019, ArisGlobal held a webinar focused on the “Key Use Cases of Automation in Pharmacovigilance.” During that event, 84% of attendees indicated a significant increase in their case volumes over the last five years. Only 15% considered their case volume increases to be ‘slight.’

It is with great excitement that we announce that Nordic Capital has entered into a definitive agreement to acquire ArisGlobal. Over these 32 years, ArisGlobal has built a sustainable and growing business that thrives on its partnerships with many life sciences companies and regulatory agencies. These customer relationships, some lasting decades, have allowed ArisGlobal to become a leading healthcare technology company with over 1200 employees across an expansive global footprint.

ArisGlobal, part of the more cautious and highly regulated life science go “all-in on AWS” by moving the entire cloud infrastructure to the AWS platform. This move benefits both ArisGlobal and to our customers.

Pharmaceutical companies, service providers, and solution providers should focus on as technology advancements continue to transform drug safety for the future. Read the blog

LifeSphere Safety MultiVigilance (LSSMV) database system has auto-translation capabilities that can translate safety narratives from English to Chinese and vice versa using advanced machine-learning technology.

Examining the challenges involved, benefits to be gained and requirements of unified regulatory and clinical business processes, as well as recommendations for taking the next steps forward.

LifeSphere Safety MultiVigilance (LSSMV) database system has auto-translation capabilities that can translate safety narratives from English to Chinese and vice versa using advanced machine-learning technology.

In order to stay compliant with NMPA requirements (submitting all post-marketing ADRs in ICH E2B (R3) format), drug manufacturers are required to procure an electronic safety database that is.....

Advanced computing methods can be used for safety monitoring and early detection of potential signals of vaccine-related adverse events. These methods work by mining open-access active-moiety databases and vast scientific literature with clinical case studies.

There has been significant changes in the way the EMA expects MAHs to handle ICSRs from the new EudraVigilance system, creating additional work for already busy pharmacovigilance departments